Clinical Edge Journal Scan

Targeted early breast screening for women with familial risk is linked to survival benefit


 

Key clinical point: Targeted breast screening in women aged 30-60 years at an increased familial risk is associated with good long-term survival.

Major finding: A total of 649 breast cancers were detected during the follow-up of 129,119 person-years. Breast cancer-specific survival at 10 years was 91.3%, which was higher than the previously reported survival in women presenting with primary breast cancer. Moreover, 10-year survival for women diagnosed at age 40 years and below was 93.8%.

Study details: This was a retrospective study of women who were offered enhanced screening with annual mammography starting at age 35 years or 5 years younger than the youngest affected relative, with the upper age limit of 50 years for women at moderate risk and 60 years for those at high risk.

Disclosures: This work was supported by the National Institute for Health Research and Prevent Breast Cancer. Dr. DG Evans received consulting fees from companies. The other authors declared no conflict of interests.

Source: Evans DG et al. Breast Cancer Res Treat. 2021 Jul 26 (in press). doi: 10.1007/s10549-021-06333-1 .

Recommended Reading

Internal mammary lymph node radiation safe over the long term
MDedge Hematology and Oncology
Polygenic breast cancer risk scores strive to overcome racial bias
MDedge Hematology and Oncology
Gender-affirming mastectomy and breast cancer screening in transmasculine patients
MDedge Hematology and Oncology
Pandemic-related drops in breast cancer screening hit hardest among medically underserved
MDedge Hematology and Oncology
Breast cancer: 10-year treatment extension with aromatase inhibitors yields no benefit
MDedge Hematology and Oncology
HR-positive breast cancer: Entinostat fails phase 3 trial
MDedge Hematology and Oncology
HER2-positive breast cancer: Add-on trastuzumab lowers recurrence and mortality
MDedge Hematology and Oncology
HER2-negative breast cancer: Adjuvant celecoxib fails phase 3 trial
MDedge Hematology and Oncology
Triple Negative Breast Cancer (TNBC): Adding ipatasertib to paclitaxel does not improve survival
MDedge Hematology and Oncology
HR-positive breast cancer: Extended intermittent letrozole yields no survival benefit
MDedge Hematology and Oncology